{"id":"W2590065183","doi":"10.1182/blood.v112.11.1559.1559","title":"Supportive Efficacy Analyses for the Phase 3 Study of Temsirolimus Versus Investigator’s Choice Therapy for the Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma.","year":2008,"lang":"en","type":"article","venue":"Blood","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Temsirolimus; Medicine; Hazard ratio; Mantle cell lymphoma; Internal medicine; Clinical endpoint; Population; Refractory (planetary science); Progression-free survival; Oncology; Randomized controlled trial; Lymphoma; Confidence interval; Chemotherapy; Discovery and development of mTOR inhibitors; Biology; PI3K/AKT/mTOR pathway","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01819116,0.0009214287,0.001963148,0.0008360704,0.0005616227,0.0008757018,0.001068151,0.001377279,0.006412625],"category_scores_gemma":[0.007917278,0.0005260071,0.006617834,0.0006773511,0.0007097973,0.001214868,0.0005650487,0.003137491,0.0008501776],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001083858,"about_ca_system_score_gemma":0.001439238,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004164927,"about_ca_topic_score_gemma":0.0007957773,"domain_scores_codex":[0.9931914,0.005487173,0.0002625104,0.0002964205,0.00048241,0.0002801885],"domain_scores_gemma":[0.9902948,0.004040772,0.002390973,0.0009739128,0.0006408954,0.001658726],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.9644604,0.004395697,0.003465611,0.0003906157,0.003534306,0.00005985969,0.00007990412,0.001247742,0.003621877,0.0001791141,0.001539078,0.01702596],"study_design_scores_gemma":[0.6211829,0.3215501,0.03684803,0.000103998,0.005780143,0.0002553364,0.00008060534,0.003991647,0.003640236,0.001020606,0.005486545,0.0000598767],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9769049,0.006847742,0.002261061,0.001226045,0.0002952513,0.004879905,0.003792163,0.0001339074,0.003659087],"genre_scores_gemma":[0.9848921,0.00098738,0.003149228,0.001021588,0.0002599704,0.003952875,0.004567593,0.00003740924,0.001131891],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01819116,"threshold_uncertainty_score":0.09620517,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09279054521882356,"score_gpt":0.3546920991419785,"score_spread":0.261901553923155,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}